Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$1.3 million.

  • Cartesian Therapeutics' Cash from Investing Activities rose 79.16% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.3 million, marking a year-over-year decrease of 181.12%. This contributed to the annual value of -$8.7 million for FY2024, which is 125.26% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Cash from Investing Activities stood at -$1.3 million for Q3 2025, which was up 50.21% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Cash from Investing Activities registered a high of $28.1 million during Q1 2023, and its lowest value of -$29.9 million during Q3 2022.
  • Its 3-year average for Cash from Investing Activities is $2.1 million, with a median of -$838,500 in 2024.
  • Data for Cartesian Therapeutics' Cash from Investing Activities shows a peak YoY increase of 5,956.63% (in 2021) and a maximum YoY decrease of 16,525.93% (in 2021) over the last 5 years.
  • Over the past 5 years, Cartesian Therapeutics' Cash from Investing Activities (Quarterly) stood at $9.7 million in 2021, then slumped by 43.54% to $5.5 million in 2022, then rose by 18.36% to $6.5 million in 2023, then slumped by 105.45% to -$354,000 in 2024, then spiked by 79.16% to -$1.3 million in 2025.
  • Its Cash from Investing Activities was -$1.3 million in Q3 2025, compared to -$2.6 million in Q2 2025 and -$1.1 million in Q1 2025.